Paradigm Biopharmaceuticals Limited
PBIGFOTCHealthcare● Active
$0.11
$-0.05(-30.00%)
Market Cap$45505675
P/E Ratio—
52W High$0.3468
52W Low$0.10086
Paradigm Biopharmaceuticals Limited (PBIGF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PBIGF · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 26, 2026EPS Actual
-$0.04
Revenue
$0.00B
Est. $0.00B · +0.0%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 26, 2026
After Market Close
PBIGF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 21, 2026 | — | — | — | — | — | — |
| — Q1 FY2026 | Feb 26, 2026 | — | -$0.04 | — | $0.00B | $0.00B | +0.0% |
| ◌ Q2 FY2025 | Apr 29, 2025 | — | — | — | — | — | — |
| — Q1 FY2025 | Feb 26, 2025 | — | -$0.01 | — | $0.00B | — | — |
| — Q4 FY2024 | Oct 30, 2024 | — | -$0.01 | — | $0.00B | — | — |
| — Q3 FY2024 | Aug 30, 2024 | — | -$0.01 | — | $0.00B | — | — |
| — Q2 FY2024 | Apr 29, 2024 | — | -$0.01 | — | — | — | — |
| — Q1 FY2024 | Mar 21, 2024 | — | -$0.11 | — | $0.00B | — | — |
Q3 FY2026
Aug 21, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 26, 2026
EPS Actual
-$0.04
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2025
Apr 29, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Feb 26, 2025
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2024
Oct 30, 2024
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2024
Aug 30, 2024
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2024
Apr 29, 2024
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Mar 21, 2024
EPS Actual
-$0.11
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q1 FY2026 | Feb 26, 2026 | — | $0.20 | $0.20 | +0.00% |
| — Q1 FY2025 | Feb 26, 2025 | — | $0.38 | $0.38 | +0.00% |
| — Q4 FY2024 | Oct 30, 2024 | — | $0.11 | $0.14 | +22.49% |
| — Q3 FY2024 | Aug 30, 2024 | — | $0.16 | $0.16 | +0.00% |
| — Q2 FY2024 | Apr 29, 2024 | — | $0.18 | $0.19 | +5.97% |
| — Q1 FY2024 | Mar 21, 2024 | — | $0.23 | $0.22 | -5.06% |
| — Q1 FY2024 | Jan 30, 2024 | — | $0.23 | $0.23 | +0.00% |
| — Q2 FY2023 | Jun 30, 2023 | — | No price data | $0.63 | — |
Q1 FY2026+0.00%
Report Date
Feb 26, 2026
EPS Beat/Miss
—
Price Before
$0.20
Price After
$0.20
Q1 FY2025+0.00%
Report Date
Feb 26, 2025
EPS Beat/Miss
—
Price Before
$0.38
Price After
$0.38
Q4 FY2024+22.49%
Report Date
Oct 30, 2024
EPS Beat/Miss
—
Price Before
$0.11
Price After
$0.14
Q3 FY2024+0.00%
Report Date
Aug 30, 2024
EPS Beat/Miss
—
Price Before
$0.16
Price After
$0.16
Q2 FY2024+5.97%
Report Date
Apr 29, 2024
EPS Beat/Miss
—
Price Before
$0.18
Price After
$0.19
Q1 FY2024-5.06%
Report Date
Mar 21, 2024
EPS Beat/Miss
—
Price Before
$0.23
Price After
$0.22
Q1 FY2024+0.00%
Report Date
Jan 30, 2024
EPS Beat/Miss
—
Price Before
$0.23
Price After
$0.23
Q2 FY2023—
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
—
Price After
$0.63
Beat Rate0 / 8 quarters
Largest Move+22.49% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PBIGF ends December
Paradigm Biopharmaceuticals Limited (PBIGF) most recently reported earnings on February 26, 2026 for Q1 FY2026, posting EPS of $-0.04 (in line with the analyst consensus of —). The next PBIGF earnings date is expected around September 1, 2026.
Each quarter, investors track PBIGF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PBIGF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PBIGF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PBIGF earnings · 4 questionsParadigm Biopharmaceuticals Limited's next earnings report is expected around September 1, 2026. PBIGF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PBIGF historically reports after market close (AMC).
PBIGF earnings datewhen is PBIGF earningsPBIGF next earnings datewhen does PBIGF report earningsPBIGF earnings calendar
▸ Source: FMP · Paradigm Biopharmaceuticals Limited SEC filings · US GAAP · Paradigm Biopharmaceuticals Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026